QC
PYXS icon

Quadrature Capital’s Pyxis Oncology PYXS Stock Holding History

Quadrature Capital’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,536
Closed -$116K – 1757
2025
Q4 		$116K Buy
+100,536
New +$355K ﹤0.01% 1078
2025
Q3 		– Sell
-12,334
Closed -$13.6K – 1406
2025
Q2 		$13.6K Buy
+12,334
New +$13.9K ﹤0.01% 997

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrature Capital's PYXS Position: Q1 2026 in Review

Quadrature Capital sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 100,536 shares — an estimated $116K sold.

Quadrature Capital first reported a position in PYXS in Q2 2025 and held it in 2 quarters. The position peaked at $116K in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Quadrature Capital reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 100,536 Pyxis Oncology shares in Q1 2026, an estimated $116K.
  • Quadrature Capital first reported a position in Pyxis Oncology in Q2 2025 and held it in 2 quarters.
  • Quadrature Capital's Pyxis Oncology position peaked at $116K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.